U.S. patents available from 1976 to present.
U.S. patent applications available from 2005 to present.

Icon_funbox Did You Know...

...that the x-ray was discovered purely by accident? When German physicist Wilhelm Konrad von Roentgen was experimenting with cathode rays in 1895, he put an activated Crookes tube in a book and went out to lunch. When he returned, he discovered that a key that had also been placed in the book showed up as an image on the developed film!

Newsletter  PatentStorm News

Make the Most of Our Site

See this month's Top Inventors and Most Cited Patents.

Stay on top of the latest innovations by subscribing to an RSS feed.

Registered users: Manage your profile.

 

Class 424/85.5 - Gamma or immune


Subclass of Class 424 - Drug, bio-affecting and body treating compositions
Definition: Subject matter in which the interferon is gamma or immune
No. of applications: 386
Last issue date: 02/16/2012


1                    
Application No.Application TitleIssue Date
20120039844COMPOSITION AND USE OF N-ALPHA-METHYLHISTAMINE DIHYDROCHLORIDE FOR THE REDUCTION OF OXYGEN RADICAL FORMATION
An improved composition and method for reducing the formation of oxygen radicals in mononuclear phagocytes is disclosed. Also provided is a method of protecting NK cells from oxidative damage inflicted by radicals produced by mononuclear phagocytes by administering a hi... 		02/16/2012
20120039848HEPATITIS C VIRUS INHIBITORS
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:

which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Conse...

02/16/2012
20120039797Antibody Therapy
The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition.... 		02/16/2012
20120034186INDOLINE SCAFFOLD SHP-2 INHIBITORS AND METHOD OF TREATING CANCER
Protein tyrosine phosphatase (PTP) Shp2 is a non-receptor PTP that involved in cell signaling and regulation of cell proliferation, differentiation, and migration. Shp2 mediates activation of kinases that are involved in the pathogenesis of human carcinoma. A high throu... 		02/09/2012
20120027846ANTI-VIRAL AZIDE CONTAINING COMPOUNDS
Methods of using azide-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to inhibit infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are me... 		02/02/2012
20120021043Nucleic Acids Comprising formula (NuGlXmGnNv)a and Derivatives Thereof as Immunostimulating Agent/Adjuvant
The present invention relates to nucleic acids of the general formula (I): (NuGlXmGnNv)a and derivatives thereof as an immunostimulating agent/adjuvant and to compositions containing same, optionally comp... 		01/26/2012
20120021036COMPOSITE NANOSTRUCTURES AND METHODS FOR MAKING AND USING THEM
The invention provides nanostructures or products of manufacture for use as ex vivo or in vivo composition (e.g., a drug, or a therapeutic, diagnostic or imaging reagent) delivery vehicles. In one aspect, the invention provides nanoparticles comprising several compartme... 		01/26/2012
20120014869MUC18 TARGETING PEPTIDES
Provided are MUC 18 targeting peptides which may be used, e.g., to therapeutically target B-I lymphocytes to reduce the influence of these cells on the metastatic potential of melanoma cells and/or to target cancerous cells, including certain melanoma and leukemia cells... 		01/19/2012
20120014914INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASES
The present invention relates to compounds of formula I:

or a pharmaceutically acceptable salt, or mixtures thereof, that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-N...

01/19/2012
20120009149Tetrameric Cytokines with Improved Biological Activity
The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-MAb DNL complex comprises an IgG antibody attached to two AD (anchor domain) moieties and four cytokine... 		01/12/2012
20120009140COMPOSTITION AND THERAPEUTIC ANTI-TUMOUR VACCINE
The invention relates to a composition which induces, in a host, a cytotoxic cell response directed against cells expressing an antigen, in particular tumour cells, and which comprises red blood cells containing said antigen. These red blood cells may be in the form of ... 		01/12/2012
20110315575Methods, Compositions and Articles of Manufacture for Contributing to the Treatment of Cancers
Methods, compositions and articles of manufacture for contributing to the treatment of cancers, including solid tumors, are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ETB) to enhance the delivery and ... 		12/29/2011
20110311474Novel Tricyclic Compounds
The invention provides compounds of Formula (I) and Formula (II)

pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defin...

12/22/2011
20110311481Methods and Compositions for Contributing to the Treatment of Cancers
Methods and compositions for contributing to the treatment of cancers, especially ovarian tumors, are disclosed. The methods and compositions utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of chemotherapeutic agent(s) (e.... 		12/22/2011
20110305631Camptothecin Conjugates of Anti-CD22 Antibodies for Treatment of B Cell Diseases
Disclosed herein are compositions and methods of use comprising combinations of anti-CD22 antibodies with a therapeutic agent. The therapeutic agent may be attached to the anti-CD22 antibody or may be separately administered, either before, simultaneously with or after ... 		12/15/2011
20110305668METHODS FOR USING INTERFERON GAMMA TO ABSORB FLUID FROM THE SUBRETINAL SPACE
Particular aspects of the invention provide methods for decreasing the amount of fluid present in the subretinal space of the eye by administering interferon gamma to the basolateral side of the retinal pigment epithelium. Adverse ocular conditions associated with the a... 		12/15/2011
20110305667USE OF A DEAD-BOX RNA HELICASE FOR INDUCING CYTOKINE PRODUCTION
The invention relates to the use of a DEAD-box RNA helicase from a yeast, a mammal, Leishmania infantum, or fragments thereof for inducing the production of cytokines by a peripheral blood mononuclear cell (PBMC) of a mammal, and to the applications thereof.... 		12/15/2011
20110300104HEPATITIS C VIRUS INHIBITORS
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:

which inhibit RNA-containing virus, particularly the Hepatitis C Virus (HCV). Conse...

12/08/2011
20110300066Combination Therapy With Anti-CD74 Antibodies Provides Enhanced Toxicity to Malignancies, Autoimmune Disease and Other Diseases
Disclosed herein are compositions and methods of use comprising combinations of anti-CD74 antibodies with a therapeutic agent. The therapeutic agent may be attached to the anti-CD74 antibody or may be separately administered, either before, simultaneously with or after ... 		12/08/2011
20110293516COMPOSITIONS AND METHODS OF USE OF TARGETING PEPTIDES AGAINST PLACENTA AND ADIPOSE TISSUES
The present invention concerns compositions comprising and methods of identification and use of targeting peptides for placenta or adipose tissue. In certain embodiments, the targeting peptides comprise part or all of SEQ ID NO:5-11, SEQ ID NO:13-22 or SEQ ID NO:144. Th... 		12/01/2011
20110286962COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS
Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination wi... 		11/24/2011
20110286966Inhibitor of Endogenous Human Interferon-gamma
Modified endogenous human interferon-gamma (hIFN-γ), biologically inactive but preserving binding affinity to the hIFN-γ receptor, has applicability in the treatment of autoimmune diseases, especially multiple sclerosis.... 		11/24/2011
20110286967LONG-ACTING INTERFERONS AND DERIVATIVES THEREOF AND METHODS THEREOF
A polypeptide and polynucleotides encoding same comprising carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to an IFN protein are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of usi... 		11/24/2011
20110280829Low Molecular Weight Sulphated Polysaccharides as Candidates for Anti-Angiogenic Therapy
Low molecular weight sulphated L-fucose polysaccharide fraction having a molecular weight ranging from 11 to 30 kDa when measured with TEST A, a sulphate content ranging from 10 and 50% w/w relative to the total weight of the fraction, a fucosis content ranging from 30 ... 		11/17/2011
20110280800IL-1 BINDING PROTEINS
Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions.... 		11/17/2011
20110274656PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HEPATITIS C, COMPRISING THE ROOTS EXTRACT OF PLATYCODON GRANDIFLORUM OR PLATYCODON GRANDIFLORUM SAPONIN COMPONENTS
The present invention relates to a pharmaceutical composition for preventing or treating Hepatitis C, comprising the roots extract of Platycodon grandiflorum and/or saponin components in Platycodon grandiflorum useful as an antiviral agent. The composition... 		11/10/2011
20110274654TRIAZOLES AS INHIBITORS OF FATTY ACID SYNTHASE
Provided herein are triazole FASN inhibitors of the formula (I):

or a pharmaceutically acceptable form thereof; wherein the variables RA, X, RB, and RC are defined herein.

... 		11/10/2011
20110274655TETRAZOLONES AS INHIBITORS OF FATTY ACID SYNTHASE
Provided herein are tetrazolone FASN inhibitors of the formula (I):

or a pharmaceutically acceptable form thereof; wherein the variables RA, RB and RC are defined herein.

... 		11/10/2011
20110274653DENDRITIC CELL IMMUNORECEPTORS (DCIR)-MEDIATED CROSSPRIMING OF HUMAN CD8+ T CELLS
Immunostimulatory compositions and methods comprising an ITIM motif-containing DC immunoreceptor (DCIR) to mediate potent crosspresentation are described herein. The inventors evaluated human CD8+ T cell responses generated by targeting antigens to dendritic cells (DCs)... 		11/10/2011
20110262398CARDIAC TREATMENT USING ANTI-FIBROTIC AGENTS
Disclosed herein are reagents and methods for detecting and treating age-related diastolic dysfunction in an animal or a human.... 		10/27/2011
20110250174STABLE IMMUNOGENIC PRODUCT COMPRISING ANTIGENIC HETEROCOMPLEXES
The invention relates to a stable immunogenic product for the induction of antibodies against one or more antigenic proteins in a subject. The invention is characterised in that it comprises proteinaceous immunogenic heterocomplexes which are formed by associations betw... 		10/13/2011
20110250173Methods and compositions for inhibition of Treg cells
The present invention relates to methods of suppressing the immune tolerance of a disease or disease antigens in a patient. The method also promotes the activity of the effector T lymphocytes. The invention includes administering a therapeutic composition that promotes ... 		10/13/2011
20110250171Compositions and Methods for Cancer Immunotherapy
The invention relates to immunotherapeutic compounds and to methods for stimulating an immune response in a subject individual at risk for developing cancer, diagnosed with a cancer, in treatment for cancer, or in post-therapy recovery from cancer or the compounds of th... 		10/13/2011
20110250172HEPATITIS C VIRUS INHIBITORS
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:

which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Conse...

10/13/2011
20110243891DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE
The present invention relates to a compound of General Formula (I) below, among others. In the Formula, Ar1 is an optionally substituted aryl or heteroaryl group; R1 is a hydrogen atom, an optionally substituted C1-C6 alkyl group, or an optionally ... 		10/06/2011
20110243892Y-SHAPE BRANCHED HYDROPHILIC POLYMER DERIVATIVES, THEIR PREPARATION METHODS, CONJUGATES OF THE DERIVATIVES AND DRUG MOLECULES, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE CONJUGATES
The present invention relates to Y-shape branched PEG derivatives of formulae (I) to (IV). The present invention also relates to conjugates of these Y-shape derivatives and drug molecules, pharmaceutical compositions comprising those conjugates.... 		10/06/2011
20110243841Antibody-Based Depletion of Antigen-Presenting Cells and Dendritic Cells
Disclosed herein are methods and compositions comprising anti-CD74 and/or anti-HLA-DR antibodies for treatment of GVHD and other immune dysfunction diseases. In preferred embodiments, the anti-CD74 and/or anti-HLA-DR antibodies are effective to deplete antigen-presentin... 		10/06/2011
20110236349Use of Epidermal Growth Factor Inhibitors in the Treatment of Viral Infection
The present invention provides methods of treating a viral infection in an individual. The methods generally involve administering to an individual an effective amount of an epidermal growth factor receptor (EGF-R) inhibitor.... 		09/29/2011
20110236304STRUCTURAL VARIANTS OF ANTIBODIES FOR IMPROVED THERAPEUTIC CHARACTERISTICS
The present invention provides substituted humanized, chimeric or human anti-CD20 antibodies or antigen binding fragments thereof and bispecific antibodies or fusion proteins comprising the substituted antibodies or antigen binding fragments thereof. The antibodies, fus... 		09/29/2011
20110229407Alpha-Fetoprotein Immu31 Antibodies and Fusion Proteins and Methods of Use Thereof
The present invention provides humanized, chimeric and human anti-alpha-fetoprotein antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the tre... 		09/22/2011
1                    
 
Sign InRegister
Username  
Password   
forgot password?